About: Tularemia Progression and it Modulation Including Mortality Remission and Enhancing of Immune System Response Using Asoxime (HI-6)     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Objective: Francisella tularensis is an intracellular pathogen causing tularemia disease. Immune system action against tularemia is limited due to lipopolysaccharide covering bacterial cell. Cholinergic anti-inflammatory pathway is a link between parasympathetic nervous system and macrophage assisted immunity. Asoxime (also known as HI-6) is a compound implicated in regulation of acetylcholinesterase as well as acetylcholine receptors. We hypothesize suitability of asoxime to modulate tularemia progression. Procedure and experiment design: Laboratory mice BALB/c were infected with F. tularensis LVS strain and challenged by application of 209 mu g/kg to 209 mg/kg of HI-6 in the experiment beginning and then the next day. Mice were sacrificed after five days. Plasma, spleen and liver were sampled. In the separate experiment, tularemia caused mortality was assessed with and without of asoxime application. Results and Conclusions: Regarding to oxidative damage of liver and spleen, asoxime altered lipid peroxidation in liver and significantly reduced oxidative damage in spleens. We also proved significant increase of plasmatic antibodies level, decrease of IL6 and steady level of IFN gamma. Mice treated with asoxime had reduced mortality when compared to the infected and untreated ones. The best protective index was calculated 2.6 for asoxime doses 2.09 and 20.9 mg/kg. Asoxime can be considered as a compound reducing detrimental impact of tularemia. Effect of asoxime on cholinergic anti-inflammatory pathway and overall practical effect is discussed.
  • Objective: Francisella tularensis is an intracellular pathogen causing tularemia disease. Immune system action against tularemia is limited due to lipopolysaccharide covering bacterial cell. Cholinergic anti-inflammatory pathway is a link between parasympathetic nervous system and macrophage assisted immunity. Asoxime (also known as HI-6) is a compound implicated in regulation of acetylcholinesterase as well as acetylcholine receptors. We hypothesize suitability of asoxime to modulate tularemia progression. Procedure and experiment design: Laboratory mice BALB/c were infected with F. tularensis LVS strain and challenged by application of 209 mu g/kg to 209 mg/kg of HI-6 in the experiment beginning and then the next day. Mice were sacrificed after five days. Plasma, spleen and liver were sampled. In the separate experiment, tularemia caused mortality was assessed with and without of asoxime application. Results and Conclusions: Regarding to oxidative damage of liver and spleen, asoxime altered lipid peroxidation in liver and significantly reduced oxidative damage in spleens. We also proved significant increase of plasmatic antibodies level, decrease of IL6 and steady level of IFN gamma. Mice treated with asoxime had reduced mortality when compared to the infected and untreated ones. The best protective index was calculated 2.6 for asoxime doses 2.09 and 20.9 mg/kg. Asoxime can be considered as a compound reducing detrimental impact of tularemia. Effect of asoxime on cholinergic anti-inflammatory pathway and overall practical effect is discussed. (en)
Title
  • Tularemia Progression and it Modulation Including Mortality Remission and Enhancing of Immune System Response Using Asoxime (HI-6)
  • Tularemia Progression and it Modulation Including Mortality Remission and Enhancing of Immune System Response Using Asoxime (HI-6) (en)
skos:prefLabel
  • Tularemia Progression and it Modulation Including Mortality Remission and Enhancing of Immune System Response Using Asoxime (HI-6)
  • Tularemia Progression and it Modulation Including Mortality Remission and Enhancing of Immune System Response Using Asoxime (HI-6) (en)
skos:notation
  • RIV/62157124:16270/12:43871455!RIV13-MSM-16270___
http://linked.open...avai/predkladatel
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I, V
http://linked.open...iv/cisloPeriodika
  • 1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 175306
http://linked.open...ai/riv/idVysledku
  • RIV/62157124:16270/12:43871455
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • cholinergic anti-inflammatory pathway; oxidative stress; inflammation; HI-6; Francisella tularensis (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • US - Spojené státy americké
http://linked.open...ontrolniKodProRIV
  • [E8FA44892591]
http://linked.open...i/riv/nazevZdroje
  • International journal of applied research in veterinary medicine
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 10
http://linked.open...iv/tvurceVysledku
  • Kuča, Kamil
  • Pikula, Jiří
  • Pohanka, Miroslav
  • Pavlis, Oto
http://linked.open...ain/vavai/riv/wos
  • 000302334100011
issn
  • 1542-2666
number of pages
http://localhost/t...ganizacniJednotka
  • 16270
is http://linked.open...avai/riv/vysledek of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 38 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software